Medtronic’s (NYSE: MDT) FQ1 results and guidance update did not spark a rally in the share price. Still, they did affirm a robust outlook that includes accelerating business growth, improving profitability, and reversing the stock price action.
The critical takeaways are that growth was present, outperformed the consensus reported by MarketBeat, and guidance was improved.
